Is ε-Aminocaproic Acid as Effective as Aprotinin in Reducing Bleeding With Cardiac Surgery?

Publisher Website
Google Scholar
Abstract
Background —Although aprotinin is known to be effective in reducing postoperative hemorrhage after cardiac surgery, ε-aminocaproic acid, an alternative antifibrinolytic, is considerably less expensive. Because the results of 3 small randomized clinical trials comparing these 2 agents directly were inconclusive, we performed a meta-analysis to compare the relative effectiveness and adverse-effect profile of these 2 agents against placebo. Methods and Results —Data from 52 randomized clinical trials published between 1985 and 1998 involving the use of ε-aminocaproic acid (n=9) or aprotinin (n=46) in patients undergoing cardiac surgery were abstracted. Our primary outcomes were total blood loss, red blood cell transfusion rates and amounts, reexploration, stroke, myocardial infarction, and mortality. The meta-analysis revealed substantial reductions in total blood loss with ε-aminocaproic acid and low-dose aprotinin (each with a 35% reduction versus placebo, P P P P Conclusions —Because the 2 antifibrinolytic agents appear to have similar efficacies, the considerably less-expensive ε-aminocaproic acid may be preferred over aprotinin for reducing hemorrhage with cardiac surgery.